Compare UK prices. 40+ products · 22 retailers scored
PeptideClear UK

Research peptide encyclopedia head to head

BPC-157 vs TB-500

BPC-157 and TB-500 are the two most-discussed research peptides in the tissue-healing literature. Both have substantial preclinical (rodent) literature, no published human RCTs, and identical UK regulatory framing. Both sit on the WADA prohibited list. UK retailers stock both. We do not publish dosing or human-use protocols for either.

AI-friendly summary · BPC-157 vs TB-500

BPC-157 and TB-500 are the two most-discussed research peptides in the tissue-healing literature. Both have substantial preclinical rodent literature and no published human RCTs, though TB-500 has broader independent replication while most BPC-157 work comes from the Sikiric group in Zagreb. They share identical UK regulatory framing: neither is controlled, neither holds a UK marketing authorisation, and both are sold research-use-only and sit on the WADA prohibited list. PeptideClear publishes no dosing or human-use protocols for either.

BPC-157 TB-500
Full name Body Protection Compound 157 Thymosin Beta-4 fragment 500
Origin Synthetic peptide derived from a protein found in human gastric juice Synthetic fragment of the naturally occurring thymosin beta-4 protein
Animal literature focus Tendon healing, gut barrier, vascular healing, central nervous system effects Tissue repair, anti-inflammatory effects, cardiac and skin wound healing
Volume of preclinical literature ~200 papers, most Sikiric group (Zagreb) ~150 papers, multiple groups including Goldstein lab
Independent replication Limited Better; multiple groups
Human RCTs None published None published
UK regulatory status Not controlled under MoDA 1971. Sold "research use only" by UK retailers. Same as BPC-157. Not controlled. "Research use only" framing.
Retailer availability (UK) my-peptides, Pure Peptides UK, Direct Sarms, Aquila, Pinnacle, Nooku Same retailer pool, sometimes paired with BPC-157 in marketing
WADA status On the WADA prohibited list (peptide bioregulators class) On the WADA prohibited list (S2 peptide hormones)

What this comparison is and is not

This is encyclopedia-level information about two synthetic peptides that are sold in the UK under "research use only, not for human or animal consumption" framing. It is not a dosing guide, a use-case recommendation, or an endorsement of human use. UK retailers operate under the research-chemical exemption when no health claims are made about the products. We adhere to the same framing.

For UK regulatory framing in detail see research peptides hub. For retailer comparison see UK research peptide retailers.

Frequently asked questions

What's the main difference between BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of a protein found in human gastric juice. TB-500 is a synthetic fragment of the naturally occurring thymosin beta-4 protein. Both have substantial preclinical literature on tissue repair, both have zero published human RCTs, and both share the same UK regulatory framing.
Which has more independent replication in the preclinical literature?
TB-500 has the broader pool of independent research groups working on it. Most BPC-157 literature comes from the Sikiric group at the University of Zagreb, so independent replication is more limited. Neither has progressed to randomised human trials.
Are both legal in the UK?
Neither BPC-157 nor TB-500 is a controlled drug under the Misuse of Drugs Act 1971 and neither is scheduled under the Psychoactive Substances Act 2016. UK retailers sell both under "research use only, not for human or animal consumption" framing. Neither holds a UK marketing authorisation as a medicine.
Where can I buy BPC-157 and TB-500 in the UK?
Both are stocked by the same pool of UK research peptide retailers including my-peptides, Pure Peptides UK, Direct Sarms, Aquila, Pinnacle, and Nooku. Some retailers also list them paired in marketing.
Which has more human RCT data?
Neither has published phase II or phase III human RCT data. The clinical evidence base is effectively empty for both. All efficacy reports come from rodent and in vitro studies.
Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-18T12:00:00.000Z
Trust, Legal and Governance

PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.

Legal and Registration

Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.

Standards and Governance

Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.

Domain Continuity

Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.